South Africa considering auto industry incentives as tariff buffer
"What we're currently considering is the possibility of expanding the automotive industry production plan so that we're able to mitigate the impact in our industry," Tau said in an interview with radio broadcaster Power FM.
"We're currently modelling what the potential package could be for the auto sector, but also for other sectors so that we can do it within the means of the country to buffer the impact."
The Automotive Production and Development Programme is an incentive programme that helps drive investment, innovation and job creation in the automotive industry. It offers various rebates and refunds on customs duties and manufacturers also receive incentives based on their production volumes.
The National Association of Automobile Manufacturers of South Africa has expressed concern over the 25% U.S. import tariff on cars, saying that it cannot be absorbed by manufacturers, which will result in additional costs for U.S. consumers and a reduced choice of South African-produced brands.
The U.S. is the third-largest destination for South African automotive exports, with approximately 35 billion rand ($1.8 billion) worth of vehicles shipped in 2024, accounting for 6.5% of total vehicle exports in 2024.
South African-based manufacturing plants operated by BMW (BMWG.DE), opens new tab, Ford (F.N), opens new tab, Isuzu (7202.T), opens new tab, Mercedes-Benz (MBGn.DE), opens new tab, Nissan (7201.T), opens new tab and Toyota (7203.T), opens new tab - which produce vehicles for global markets, including the U.S. - will be severely impacted NAAMSA added.
($1 = 19.3878 rand)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Evening Standard
26 minutes ago
- Evening Standard
BP fuels FTSE 100 but soft US data tempers gains
The London-based brewer and distiller, which owns brands ranging from Guinness stout to Johnnie Walker whisky, on Tuesday reported a decline of more than a third in its bottom line in the financial year that ended in June, as a slight decline in net sales was compounded by impairment and restructuring costs, unfavourable currency movements, and narrowed operating margins.
Telegraph
27 minutes ago
- Telegraph
Trump threatens 250pc tariffs on drug imports
The president was also critical of India after the country's foreign ministry accused the US and the EU of double standards on buying Russian oil. The US is due to impose 25pc tariffs on imports from India but Trump threatened to lift this further in his latest escalation. 'We settled on 25pc but I think I'm going to raise that very substantially over the next 24 hours because they are buying Russian oil, they are fuelling the war machine, and if they're going do that I'm not going to be happy,' he said, adding that India had 'not been a good trading partner'. 'The sticking point with India is that tariffs are too high ... They will give us zero tariffs and they're going to let us go in but that's not good enough because of what they are doing with oil.' Mr Trump also renewed his attacks on Jerome Powell, the chairman of the Federal Reserve, and repeated his calls for the central bank to cut interest rates. 'Jay Powell is highly political and I call him ... Too Late Jerome, Too Late Powell,' he said. Mr Trump added that Scott Bessent, the US treasury secretary, 'does not want' to be chairman of the Federal Reserve but said that there were four others in the running for the position. Mr Powell's term as chairman of the Federal Reserve ends in May 2026.
BreakingNews.ie
27 minutes ago
- BreakingNews.ie
Trump wants to initially impose 'small tariff' on pharma imports before rising to 150%
President Donald Trump said on Tuesday that the United States would initially place a "small tariff" on pharmaceutical imports before hiking it to 150 per cent within 18 months and eventually to 250 per cent in an effort to boost domestic production. "In one year, one-and-a-half years maximum, it's going to go to 150 per cent and then it's going to go to 250 per cent because we want pharmaceuticals made in our country," Trump told CNBC in an interview. Advertisement He did not specify the initial tariff rate on pharmaceuticals. Trump said last month that pharmaceutical tariffs could reach as high as 200 per cent. He said in February that sectoral tariffs on pharmaceuticals and semiconductor chips would start at "25 per cent or higher," rising substantially over the course of a year. Trump said on Tuesday that he plans to announce tariffs on semiconductors and chips in the "next week or so," but gave no further details. The United States has been conducting a national security review of the pharmaceutical sector, and the industry has been preparing for possible sector-specific tariffs. The administration has not announced when the results of that probe will be released. Several drugmakers have pledged multibillion-dollar investments in US manufacturing as Trump threatens import tariffs, with AstraZeneca recently committing $50 billion to expand its American operations. Advertisement PhRMA, the main lobbying group for the industry, did not immediately respond to a request for comment. Ireland Cork town nervous as Trump seeks to lure pharma in... Read More A framework agreement between the United States and the EU sets out that tariffs on pharmaceuticals and semiconductors are currently zero, but if the United States raises tariffs following its import investigation, they will be capped at 15 per cent. The pharmaceutical sector employs around 45,000 people in Ireland and is one of the country's major exports to the US. Total Irish exports were valued at €223.8 billion last year, with roughly one third going to the US. Of the €72.6 billion in US imports from Ireland, approximately €58 billion relates to pharmaceuticals and chemicals leaving Ireland.
